Antidepressants: new safety measures for all patients to improve communication of the risk of suicidal thoughts and behaviours and persistent sexual dysfunction

• All antidepressants now require enhanced safety communication about risks of suicidal ideation/behaviour and persistent sexual dysfunction to ensure informed patient consent before treatment initiation
• New safety measures aim to improve risk disclosure and patient understanding, addressing previously under-communicated adverse effects that may impact treatment adherence and outcomes
• Clinicians should proactively discuss these specific risks during antidepressant counselling, particularly with younger patients at higher risk of suicidality and those concerned about sexual side effects

New safety measures are now being implemented to improve how the risks of suicidal thoughts and behaviours and persistent sexual dysfunction are communicated to patients taking antidepressant medications.

ClinicaliQ summarises and contextualises external updates for clinical awareness, then links to the original publisher for the full article and most current context.